-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Novel RET Inhibitors Promising in Chinese Patients with RET-fusion Positive NSCLC
The results of two studies presented at the 2021 World Conference on Lung Cancer—LIBRETTO-321 and ARROW—indicate that the selective RET inhibitors selpercatinib and pralsetinib are promising treatment options for patients in China with RET-fusion positive NSCLC. According to the studies’ discussant Shengxiang (Henry) Ren, MD, PhD, of Shanghai Pulmonary Hospital, Tongji University, Shanghai, China, both…
-
Second-Line Platinum-Doublet Regimens Reasonable in SCLC
Use of platinum-doublet chemotherapy regimen as second-line treatment for patients with relapsed small-cell lung cancer (SCLC) was a reasonable option compared with nonplatinum-based regimens, according to data from a meta-analysis presented at the WCLC Congress 2021. “Optimal second-line chemotherapy for patients with relapsed SCLC remains unclear,” according to study presenter Takashi Sato, MD, PhD, of…
-
Multifaceted Initiative Launches Aimed at Reducing Lung Cancer Deaths 25% by 2030
The Baptist Cancer Center in Memphis, Tennessee, has launched a new initiative that comprises seven components that will address prevention, diagnosis, and treatment of lung cancer through smoking cessation, low-dose CT screening, algorithmic management of incidentally detected lung nodules, multidisciplinary decision-making and care, high-quality surgical care, high-quality pathologic evaluation (including biomarker testing), and expanded access…
-
Increasing Adherence to CT Lung Cancer Screening Programs
Two large-scale, randomized controlled trials—the U.S. National Lung Screening Trial (NLST; n = 53,454) and the Dutch–Belgian Randomized Lung Cancer Screening Trial (NELSON; n = 15,792)—have demonstrated that lung cancer screening (LCS) with low-dose CT substantially reduces lung cancer mortality in a high-risk population.1,2 Despite the conclusive evidence for the effectiveness of LCS, national data…
-
COVID-19 and Lung Cancer
Data from multiple groups1,2 have shown the significant impact of COVID-19 infection among patients with malignancies, leading to high overall morbidity and mortality; this includes our own institution,3 which saw numerous cases of COVID-19 very early in the pandemic. Lung cancer stood out as the cancer (along with hematological malignancies) most significantly impacted by this…
-
Determining Adjuvant Therapy Through Recurrence Prediction: New Investigations
Amid growing interest in validating relapse-prediction models, team links high-grade histology, even if not predominant, with worse outcomes in EGFR-mutated stage 1 NSCLC.
-
Psychosocial Needs Remain Largely Unmet for Patients with Lung Cancer, Caregivers
There is a critical need for psychosocial services in the lung cancer care pathway, according to a presentation by Anne-Marie Baird, BS, PhD, on behalf of Lung Cancer Europe (LUCE), at the WCLC Congress 2021. “We are all aware that person-centered care must focus on the needs of the person including their psychosocial needs,” Dr.…
-
Advocacy for Patients With Lung Cancer: Getting Involved at the Government Level in the United States
Every meeting begins with sharing your story. In summary, this is mine: My name is Liz, and I’m one of your constituents. I was diagnosed with lung cancer 15 years ago. During those 15 years, I have been on some sort of treatment for my disease all but 8 months. I am a direct beneficiary…
-
Pembrolizumab Plus Platinum-Doublet Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Unresectable, Locally Advanced Stage III NSCLC: The KEYNOTE-799 Trial in Perspective
Approximately one-third of patients with NSCLC are diagnosed with unresectable, locally advanced (LA) stage III disease.1 Historically, the standard of care for these patients has been concurrent platinum-based chemotherapy with definitive thoracic radiation therapy (cCRT), 2 garnering a median OS of approximately 28 months and 5-year OS rates of 15% to 30%, at best. The…
-
The Evolution of Palliative Care for Metastatic Lung Cancer
In August 2010, Dr. Jennifer Temel and her colleagues1 reported in the New England Journal of Medicine that patients who received early palliative care integrated with standard oncologic care from the time of diagnosis of metastatic NSCLC experienced significant improvements in quality of life and mood, received less aggressive care at the end of life,…
View ILCN Archives
Provider Resources
Popular Articles